Agence d’information d’Afrique centrale [4 February 2019]
“Kinshasa autorise la vente d’un médicament contre la maladie du sommeil” – “Kinshasa authorises the sale of a drug for sleeping sickness”
Agence d’information d’Afrique centrale [1 February 2019]
“Lutte contre la maladie du sommeil: la RDC approuve un premier traitement par voie orale” – “Fight against sleeping sickness: the DRC approves the first oral treatment”
Sina Pharmaceutical News [1 February 2019]
“首款全面治疗昏睡病口服药：赛诺菲Fexinidazole获批” – “The first comprehensive oral treatment for sleeping sickness: Sanofi’s fexinidazole approved“
IP Watch [1 February 2019]
“Current R&D causes high prices in drugs; New model needed to make drugs more affordable, speakers say”
The Telegraph [31 January 2019]
“Revolutionary sleeping sickness drug approved for use in DRC”
Forum des As [31 January 2019]
“La RDC célèbre le premier anniversaire de la Journée Nationale de la lutte contre la THA” – “The DRC celebrates the first anniversary of the National HAT Day”
Paris/Geneva – 30 January 2019
Marketing authorization of fexinidazole for the treatment of Trypanosoma brucei gambiense human African trypanosomiasis, more commonly known as sleeping sickness, has been granted in the Democratic Republic of Congo (DRC). This approval paves the way for the distribution of fexinidazole in endemic countries this year, with another submission planned in Uganda.
Health Policy Watch [23 January 2019]
“Top global health policy issues – What to watch in 2019”
19 February 2019
- Jean-François Alesandrini, Senior Advisor, External Affairs and Executive Office, and Florent M’Bo, HAT Platform Coordinator – discussion on access to medicine
Décision Santé [25 October 2018]
“De l’effervescence dans le comprimé” – “Effervescence in the tablet”
To help inform the Canadian government’s approach to biomedical innovation, particularly as relates to innovations of public health importance, DNDi has submitted a contribution providing concrete evidence of DNDi’s experience implementing needs-driven, open, collaborative R&D. The contribution recommends a series of progressive policy steps Canada can support to re-orient the global biomedical R&D system so that it (1) prioritizes patient and public health needs; (2) is sustainably financed; and (3) incorporates global norms that will enable the discovery, development, and delivery of and equitable access to innovations of public health importance.
IP Watch [15 October 2018]
“‘The People’s Prescription’: new report calls for value creation instead of value extraction in pharmaceutical R&D”
UCL News [15 October 2018]
“The health innovation system is ‘broken’ and failing patients”
IP Watch [20 September 2018]
“WHO releases draft roadmap for access to medicines; comments show polarised views”
10 September 2018
As a contribution to the World Health Organization roadmap on access to medicines and vaccines, Dr Bernard Pécoul noted the importance of including concrete deliverables in the short-, medium-, and long-term, including prioritization of R&D, open and collaborative approaches to innovation, regulatory infrastructure, and solving gaps in diagnostics and specific needs of children.
Recife, Brazil – September 2018
DNDi and the Oswaldo Cruz Foundation, along with diverse national stakeholders, are partnering to improve access to diagnosis and treatment for Chagas disease in Brazil. The collaborative project was launched during the 54th Congress of the Brazilian Society of Tropical Medicine held in the city of Recife in northeast Brazil.